January 31, 2022

Primary Sclerosing Cholangitis

Study title A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VISTAS) Disease or condition Primary […]
January 31, 2022

Nonalcoholic Steatohepatitis (NASH)

  Study title A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) (Harmony) Disease or condition NASH-Nonalcoholic Steatohepatitis Study type Interventional  (Clinical […]
January 31, 2022

Nonalcoholic Steatohepatitis (NASH)

  Study title A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and […]
September 10, 2021

Nonalcoholic Steatohepatitis (NASH)

  Study title A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and […]
May 31, 2021

Ulcerative Colitis

Study title Phase 1, Open Label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in […]
May 31, 2021

Ulcerative Colitis

Study title A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR) Disease or condition Ulcerative colitis Study type Interventional  (Clinical Trial) […]
May 31, 2021

Primary Sclerosing Cholangitis

Study title A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and […]
May 31, 2021

Primary Biliary Cholangitis

Study title Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis Disease or condition Primary biliary cholangitis Study […]
May 31, 2021

Nonalcoholic Steatohepatitis (NASH)

Study title HANMI: A Phase 2, Randomized, Double-Blind Study to Evaluate HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH; Protocol: HM-TRIA-201 Disease or […]